PREVAIL I Cluster Vaccination Study With rVSVΔG-ZEBOV-GP as Part of a Public Health Response in Liberia

In November 2015, a 15-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F. Kennedy Medical Center in Monrovia, Liberia. Two additional family members received a diagnosis of EVD. The protocol for a phase 2 placebo-controlled trial of 2 Ebola vaccines was amended and approve...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 219; no. 10; pp. 1634 - 1641
Main Authors:	Bolay, Fatorma K, Grandits, Greg, Lane, H Clifford, Kennedy, Stephen B, Johnson, Melvin P, Fallah, Mosoka P, Wilson, Barthalomew, Njoh, Wissedi S, McNay, Laura A, Hensley, Lisa E, Higgs, Elizabeth S
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 19-04-2019
Subjects:	Adolescent Adult Aged Antibody response Contact Tracing Diagnosis Disease Outbreaks - prevention & control Ebola Vaccines - administration & dosage Ebola Vaccines - adverse effects Ebola Vaccines - immunology Ebola virus Ebolavirus Ebolavirus - immunology Female Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control Humans Immunization Immunogenicity Liberia Major and Brief Reports Male Middle Aged Outbreaks Public health Vaccination - statistics & numerical data Vaccines Liberia Ebola virus Liberia vaccine cluster vaccination outbreak response ring vaccination PREVAIL rVSVΔG-ZEBOV-GP vaccine Ebola virus disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In November 2015, a 15-year-old boy received a diagnosis of Ebola virus disease (EVD) at the John F. Kennedy Medical Center in Monrovia, Liberia. Two additional family members received a diagnosis of EVD. The protocol for a phase 2 placebo-controlled trial of 2 Ebola vaccines was amended and approved; in 4 days, a single-arm cluster vaccination trial using the Merck rVSVΔG-ZEBOV-GP vaccine was initiated. Here, we evaluate the safety and immunogenicity of the vaccine and discuss challenges for its implementation in a small Ebola outbreak. We conducted a ring vaccination study among contacts and contacts of close contacts of EVD cases a in Monrovia. Participants were evaluated 1 and 6 months after vaccination. Among 650 close contacts and contacts of close contacts of EVD cases, 210 (32%) consented and were vaccinated with rVSVΔG-ZEBOV-GP. Of those vaccinated, 189 (90%) attended the month 1 follow-up visit; 166 (79%) attended the month 6 visit. No serious adverse events were reported. Among 88 participants without an elevated antibody level at baseline, 77.3% (95% confidence interval, 68.5-86.1) had an antibody response at 1 month. The Merck rVSVΔG-ZEBOV-GP vaccine appeared to be safe and immunogenic among the vaccinated individuals. However, fewer than one third of eligible individuals consented to vaccination. These data may help guide implementation decisions for of cluster vaccination programs in an Ebola cluster outbreak response situation.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0022-1899 1537-6613
DOI:	10.1093/infdis/jiy698